Browsing Tag
Wells Fargo
50 posts
JPMorgan earns $15.3bn but disappoints Wall Street. What went wrong in Q3?
JPMorgan Chase delivered higher third-quarter revenue and profit, but weaker fixed-income trading, rising expenses and an investment securities loss contributed to an earnings miss.
IES Holdings completes $691m DBM Global acquisition as structural steel and data center exposure expands
IES Holdings completed its $691 million DBM Global acquisition, adding a $1.5 billion structural steel business. Find out what changes next.
Rocket Lab eliminates $3.6bn bridge loan as Iridium acquisition financing takes shape
Rocket Lab fully funds its $8 billion Iridium acquisition after raising $1.94 billion in equity and eliminating a $3.6 billion bridge loan.
Socure raises $156m at $5.2bn valuation and buys Fravity for agentic fraud
Socure has raised $156 million at a $5.2 billion valuation while acquiring Fravity, combining identity verification, fraud decisioning and agentic investigations as AI-driven attacks push financial institutions toward more automated risk operations.
SOCAR commits $1.65bn to Comstock Resources assets as Jerry Jones backs Haynesville expansion
Comstock Resources targets a major debt reduction through a $1.65 billion SOCAR deal and $450 million Jerry Jones-backed Haynesville drilling venture.
Sandisk (SNDK) targets 80% gross margins and 100% cash return through FY2030
Sandisk's FY2028-2030 model targets 80% non-GAAP gross margins and 100% excess cash return, testing whether NBM contracts have broken NAND's cyclicality.
CenterPoint Energy (CNP) Q2 2026 beats: Houston load queue swells to 14 GW, capex plan lifted $1.2bn
CenterPoint Energy submits 14 GW of Houston load via ERCOT Batch Zero, a 65% jump over current peak, and lifts its 10-year capex plan to $66.7 billion.
ATEC remains 63% below its 52-week high, can Alphatec Holdings’ surgical growth revive sentiment?
Alphatec Holdings, Inc. is preparing for a series of investor meetings that could sharpen market attention on its growth strategy, margin expansion and ability to convert rising spine-surgery volumes into sustainable cash generation.
MaxLinear (NASDAQ: MXL) slides 22% as AI expectations outrun its Q2 beat
MaxLinear stock fell 22% despite strong Q2 results. Can optical AI growth, rising margins and Q3 guidance justify MXL’s valuation?
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.